The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Sitaxentan     N-(4-chloro-3-methyl-1,2- oxazol-5-yl)-2-[2...

Synonyms: Sitax, Sitaxsentan, CHEMBL282724, SureCN803344, cc-390, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Sitaxsentan

 

High impact information on Sitaxsentan

 

Chemical compound and disease context of Sitaxsentan

 

Biological context of Sitaxsentan

 

Anatomical context of Sitaxsentan

 

Associations of Sitaxsentan with other chemical compounds

 

Gene context of Sitaxsentan

 

Analytical, diagnostic and therapeutic context of Sitaxsentan

References

  1. Sitaxsentan therapy for pulmonary arterial hypertension. Barst, R.J., Langleben, D., Frost, A., Horn, E.M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V.F., Robbins, I.M., Zwicke, D., Duncan, B., Dixon, R.A., Frumkin, L.R. Am. J. Respir. Crit. Care Med. (2004) [Pubmed]
  2. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo, J.E., Arthur, A.S., Louis, H.G., West, K., Kassell, N.F., Lee, K.S., Helm, G.A. Neurosurgery (1998) [Pubmed]
  3. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Tilton, R.G., Munsch, C.L., Sherwood, S.J., Chen, S.J., Chen, Y.F., Wu, C., Block, N., Dixon, R.A., Brock, T.A. Pulmonary pharmacology & therapeutics. (2000) [Pubmed]
  4. Drug treatment of pulmonary arterial hypertension: current and future agents. Hoeper, M.M. Drugs (2005) [Pubmed]
  5. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. Wu, C., Decker, E.R., Blok, N., Bui, H., You, T.J., Wang, J., Bourgoyne, A.R., Knowles, V., Berens, K.L., Holland, G.W., Brock, T.A., Dixon, R.A. J. Med. Chem. (2004) [Pubmed]
  6. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Podesser, B.K., Siwik, D.A., Eberli, F.R., Sam, F., Ngoy, S., Lambert, J., Ngo, K., Apstein, C.S., Colucci, W.S. Am. J. Physiol. Heart Circ. Physiol. (2001) [Pubmed]
  7. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Langleben, D., Hirsch, A.M., Shalit, E., Lesenko, L., Barst, R.J. Chest (2004) [Pubmed]
  8. Prolonged Anti-Hypertensive Effects of Oral Sitaxsentan, a Selective ET(A) Endothelin Receptor Antagonist, in Spontaneoulsy Hypertensive Hamsters. Rubinstein, I. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy (2006) [Pubmed]
  9. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. Benza, R.L., Mehta, S., Keogh, A., Lawrence, E.C., Oudiz, R.J., Barst, R.J. J. Heart Lung Transplant. (2007) [Pubmed]
  10. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Doggrell, S.A. Expert opinion on investigational drugs. (2002) [Pubmed]
  11. Sitaxsentan for treatment of pulmonary hypertension. Wittbrodt, E.T., Abubakar, A. The Annals of pharmacotherapy (2007) [Pubmed]
  12. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Ooi, H., Colucci, W.S., Givertz, M.M. Circulation (2002) [Pubmed]
  13. Sitaxsentan (ICOS-Texas Biotechnology). Wu-Wong, J.R. Current opinion in investigational drugs (London, England : 2000) (2001) [Pubmed]
  14. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Givertz, M.M., Colucci, W.S., LeJemtel, T.H., Gottlieb, S.S., Hare, J.M., Slawsky, M.T., Leier, C.V., Loh, E., Nicklas, J.M., Lewis, B.E. Circulation (2000) [Pubmed]
  15. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., Kohan, D.E. Exp. Biol. Med. (Maywood) (2006) [Pubmed]
  16. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction. Holm, P. Scandinavian cardiovascular journal. Supplement. (1997) [Pubmed]
  17. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Barst, R.J., Langleben, D., Badesch, D., Frost, A., Lawrence, E.C., Shapiro, S., Naeije, R., Galie, N. J. Am. Coll. Cardiol. (2006) [Pubmed]
  18. Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass. Joffs, C., Walker, C.A., Hendrick, J.W., Fary, D.J., Almany, D.K., Davis, J.N., Goldberg, A.T., Crawford, F.A., Spinale, F.G. J. Thorac. Cardiovasc. Surg. (2001) [Pubmed]
 
WikiGenes - Universities